// App-Quantinova.ai

924 : CHIEF-PD: Cholinesterase Inhibitor to prEvent Falls in Parkinson’s Disease

Researchers

Presenter

  • S. Neumann

Principal Investigators

  • J. Taylor

  • A. Bamford

  • C. Metcalfe

  • D.M Gaunt

  • A. Whone

  • D. Steeds

  • S.R Emmett

  • W. Hollingworth

  • Y. Ben-Shlomo

  • E. Henderson

Medical Centers

  • N/A

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Parkinson's disease

Biomarkers

  • Butyrylcholinesterase

  • MDS-Unified Parkinson's Disease Rating Scale

Drug/Treatment

  • Rivastigmine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved